Skip to content

Study · Not a test of the peptide alone · 2026

2 results

A bone optimization rheumatology clinic increases anabolic bone agent use and reduces mechanical complications in adult spinal deformity surgery.

Jain H, Sarikonda A, Ahluwalia R, Zakieh O, Montgomery A, Navid W, Raj P, Baker CR, Chanbour H, Younus I, Zeoli T, Jonzzon S and 6 more

Show all authors

Zuckerman A, Bobo Tanner S, Lugo-Pico JG, Abtahi AM, Stephens BF, Zuckerman SL

Spine deformity14 Feb 2026Cited by 4 (Europe PMC)

PMID41688596 (opens in a new tab)PMCIDPMC13282223 (opens in a new tab)DOI10.1007/s43390-026-01307-z (opens in a new tab)PepBankPUB-41688596
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

PurposeThough the use of anabolic bone agents has proven effective in adult spinal deformity (ASD) surgery, prescription and approval of these medications remains a challenge. In osteopenic/osteoporotic patients undergoing ASD surgery, we sought to determine the impact of a bone optimization clinic on: (1) prescription patterns of anabolic agents, (2) mechanical complications, and (3) reoperation.MethodsA retrospective cohort study (2009-23) was performed for osteopenic/osteoporotic patients undergoing ASD surgery with ≥ 2-year follow-up. The study period was binarized into before/after a bone optimization clinic was established (2009-19 vs. 2020-23). The primary outcomes were: (1) use of anabolic agents prior to surgery (Teriparatide, Abaloparatide, and Romosozumab-aqqg), (2) mechanical complications, and (3) reoperation. Multivariable regression controlling for age, sex, body mass index, and operative time was performed.ResultsOf 126 patients (mean age 68 ± 10yrs; 86% female) undergoing ASD surgery with osteopenia (80%) or osteoporosis (20%), 91 (72%) were before the bone optimization clinic and 35 (28%) were after. Similar rates of osteoporosis in both groups were seen (pre-21% vs. post-17%, p = 0.638). After the bone optimization clinic, more patients received preoperative anabolic therapy (54% vs. 23%, p < 0.001) and for a longer duration (98 ± 156 vs. 40 ± 109 days, p = 0.027). Overall mechanical complications decreased significantly (49% vs 81%, p < 0.001) as did reoperation for mechanical complications (6% vs. 44%, p < 0.001). Multivariable regression showed that a bone optimization clinic independently improved the use of preoperative anabolic agents (OR = 5.3, 95%CI:2.1-13.4, p < 0.001) and reduced the risk of mechanical complications (OR = 0.2 95%CI:0.1-0.5, p < 0.001) and reoperation for mechanical complications (OR = 0.1, 95%CI:0.1-0.4, p < 0.001).ConclusionIn osteopenic/osteoporotic patients undergoing ASD surgery, a bone optimization clinic was independently associated with increased prescription rates and duration of anabolic bone agents, reduced mechanical complications, and reduced reoperation for mechanical complications.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 01HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In spinal deformity surgery patients, clinic establishment was linked to more pooled preoperative anabolic therapy use, including abaloparatide, than before establishment.

    In plain wordsThe clinic was linked to more use of pooled bone drugs, including abaloparatide, than before the clinic.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreasePreoperative anabolic therapy use
    Study

    n = 126

    Comparator
    Before clinic establishment
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Anabolic therapy use
    54%
    After clinic
    Anabolic therapy use
    23%
    Before clinic
    Adjusted odds ratio
    5.3 OR
    Clinic versus before clinic

    Source sentences

    Summary
    After the bone optimization clinic, more patients received preoperative anabolic therapy (54% vs. 23%, p < 0.001) and for a longer duration (98 ± 156 vs. 40 ± 109 days, p = 0.027).
    2 context sentences
    Summary · context
    A retrospective cohort study (2009-23) was performed for osteopenic/osteoporotic patients undergoing ASD surgery with ≥ 2-year follow-up.
    Summary · context
    The primary outcomes were: (1) use of anabolic agents prior to surgery (Teriparatide, Abaloparatide, and Romosozumab-aqqg), (2) mechanical complications, and (3) reoperation.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 02HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In spinal deformity surgery patients, clinic establishment was linked to longer pooled anabolic treatment duration, including abaloparatide, than before establishment.

    In plain wordsThe clinic was linked to longer treatment with pooled bone drugs, including abaloparatide, than before the clinic.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreasePreoperative anabolic therapy duration
    Study

    n = 126

    Comparator
    Before clinic establishment
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Mean therapy duration
    98 days
    After clinic
    Mean therapy duration
    40 days
    Before clinic

    Source sentences

    Summary
    After the bone optimization clinic, more patients received preoperative anabolic therapy (54% vs. 23%, p < 0.001) and for a longer duration (98 ± 156 vs. 40 ± 109 days, p = 0.027).
    2 context sentences
    Summary · context
    A retrospective cohort study (2009-23) was performed for osteopenic/osteoporotic patients undergoing ASD surgery with ≥ 2-year follow-up.
    Summary · context
    The primary outcomes were: (1) use of anabolic agents prior to surgery (Teriparatide, Abaloparatide, and Romosozumab-aqqg), (2) mechanical complications, and (3) reoperation.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.